Literature DB >> 28848793

Is CA 19-9 of Any Help in the Management of Cholangiocarcinoma?

Marília Cravo1.   

Abstract

Entities:  

Keywords:  CA 19-9; Cholangiocarcinoma; Prognosis

Year:  2017        PMID： 28848793      PMCID： PMC5553391          DOI： 10.1159/000457910

Source DB:  PubMed          Journal:  GE Port J Gastroenterol        ISSN： 2387-1954


× No keyword cloud information.
  8 in total

1.  Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma.

Authors:  W R Jarnagin; Y Fong; R P DeMatteo; M Gonen; E C Burke; J Bodniewicz BS; M Youssef BA; D Klimstra; L H Blumgart
Journal:  Ann Surg       Date:  2001-10       Impact factor: 12.969

2.  Does the elevation of serum carbohydrate antigen 19-9 level predict poor overall survival in patients with hepatocellular carcinoma?

Authors:  Yan-Yan Wang; Jian-Hong Zhong; Zhan Lu; Hong-Gui Qin; Le-Qun Li
Journal:  Tumour Biol       Date:  2015-10-30

3.  CA 19-9 as a Marker of Survival and a Predictor of Metastization in Cholangiocarcinoma.

Authors:  Rosa Coelho; Marco Silva; Eduardo Rodrigues-Pinto; Hélder Cardoso; Susana Lopes; Pedro Pereira; Filipe Vilas-Boas; João Santos-Antunes; José Costa-Maia; Guilherme Macedo
Journal:  GE Port J Gastroenterol       Date:  2017-02-23

4.  Preoperative CA 19-9 kinetics as a prognostic variable in radiographically resectable pancreatic adenocarcinoma.

Authors:  Erin G Brown; Robert J Canter; Richard J Bold
Journal:  J Surg Oncol       Date:  2014-10-20       Impact factor: 3.454

5.  Improved outcomes after aggressive surgical resection of hilar cholangiocarcinoma: a critical analysis of recurrence and survival.

Authors:  Akshat Saxena; Terence C Chua; Francis C Chu; David L Morris
Journal:  Am J Surg       Date:  2011-09       Impact factor: 2.565

6.  Tumor markers as a diagnostic key for hilar cholangiocarcinoma.

Authors:  B Juntermanns; S Radunz; M Heuer; S Hertel; H Reis; J P Neuhaus; S Vernadakis; T Trarbach; A Paul; Gernot M Kaiser
Journal:  Eur J Med Res       Date:  2010-08-20       Impact factor: 2.175

7.  Clinical value of preoperative serum CA 19-9 and CA 125 levels in predicting the resectability of hilar cholangiocarcinoma.

Authors:  Hai-Jie Hu; Hui Mao; Yong-Qiong Tan; Anuj Shrestha; Wen-Jie Ma; Qin Yang; Jun-Ke Wang; Nan-Sheng Cheng; Fu-Yu Li
Journal:  Springerplus       Date:  2016-04-30

Review 8.  Diagnostic Accuracy of Serum CA19-9 in Patients with Cholangiocarcinoma: A Systematic Review and Meta-Analysis.

Authors:  Bin Liang; Liansheng Zhong; Qun He; Shaocheng Wang; Zhongcheng Pan; Tianjiao Wang; Yujie Zhao
Journal:  Med Sci Monit       Date:  2015-11-18
  8 in total
  2 in total

Review 1.  Circulating Tumor DNA in Biliary Tract Cancer: Current Evidence and Future Perspectives.

Authors:  Alessandro Rizzo; Angela Dalia Ricci; Simona Tavolari; Giovanni Brandi
Journal:  Cancer Genomics Proteomics       Date:  2020 Sep-Oct       Impact factor: 4.069

2.  The Prognostic Value of the CA19-9/TBIL Ratio in Patients with Biliary Tract Cancers (BTCs): A Retrospective Study.

Authors:  Jianchun Xiao; Li Wang; Tao Hong; Binglu Li; Wei Liu; Qiang Qu; Chaoji Zheng; Xiaodong He
Journal:  J Oncol       Date:  2021-02-23       Impact factor: 4.375
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.